SEMINAR OVERVIEW

This seminar series will provide updates on the diagnosis and treatment of the dominant forms of viral hepatitis and explore the latest data on advancing liver disease, hepatocellular carcinoma, fatty liver disease and other hepatic conditions. Faculty experts will deliver state-of-the-art material utilizing a curriculum that features lectures, case analysis, current clinical trial outcomes and progress reports on promising prevention approaches and emerging therapies. The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment, and care management approaches in a setting that stresses interactive learning, audience participation, and collaborative discussion. Available in two formats, the content may be explored as both a live, face-to-face seminar or a web-based, self-paced Enduring Material. It is even possible to combine the two modalities. Either way, the goal of this CME activity is to limit future cases and improve the outcomes of those already infected.

WHY SHOULD YOU ATTEND?

▸ UPDATE your clinical knowledge with expert faculty and internationally recognized studies
▸ VALIDATE your clinical decision processes and patient care approaches
▸ COLLABORATE with local colleagues to discuss new diagnostic and treatment options

FUTURE EVENTS:

MARCH 4
Embassy Suites, Magnificent Mile
Chicago, IL

MARCH 18
Embassy Suites, Magnificent Mile
Chicago, IL

APRIL 22
Westin Resort and Spa
Washington, DC

MARCH 31–APRIL 1
Las Vegas, NV

APRIL 22
Las Vegas, NV

MAY 4
University of Louisville CTR Building
Louisville, KY

MAY 22
Hilton Costa Mesa
Costa Mesa, CA

FUTURE EVENTS: Sept. 28: St. Louis, MO
Oct. 14: San Diego, CA

For more information or to register for either the live or enduring material, please go to: https://bit.ly/hepandCLD23 for more details.

PREVENTION & THERAPIES FOR HEPATITIS AND CHRONIC LIVER DISEASE

An evidence-based, hybrid seminar series focused on Viral Hepatitis, ESLD, HCC, PBC and NASH

NEW FOR THE 2023 SEMINAR SERIES

▸ A Completely Updated Curriculum Including New Research Outcomes, Clinical Cases, and Benchmarked Lectures
▸ The Latest Findings from Key Presentations from AASLD and EASL
▸ Latest trends in the Diagnosis and Treatment of Liver Cancer
▸ How Alcohol and Alcohol Abuse Drive Advanced Liver Disease and Liver Cancer
▸ Breakthroughs in Fatty Liver Disease
▸ Clinical breakthroughs in Delta Hepatitis and Hepatorenal Syndrome
▸ A Hybrid Delivery Platform that utilizes live, F-2-F Presentations and/or Web-based lectures to optimize learning outcomes and time efficiency

Available as a live, in-person seminar or a web-based learning activity.
This seminar is also available as a self-paced, Web-based learning activity that has all the content of the live event and a faculty of national experts. Engage in the seminar at a convenient time and place.

COURSE DIRECTOR
Paul Pockros, MD, FAASLD, FACC
Director, Liver Disease Center, Scripps Clinic Medical Director, SC Liver Research Consortium

EDUCATIONAL OBJECTIVES
After attending this activity, participants should be able to:
- Review the history, epidemiology, demographics, natural history, immunology, and pathophysiology that leads to increased incidence of viral hepatitis
- Explore the factors that have led to reactivation of Hepatitis B and the diagnosis and treatment guidelines for Delta Hepatitis
- Formulate and implement strategies for preventing, diagnosing, treating, and/or referring patients with viral hepatitis
- Summarize the leading causes of the progression of chronic liver disease, hepatorenal syndrome, ascites, and hepatic encephalopathy.
- Discuss the current/emerging therapies for liver disease
- Explore the impact of alcohol on liver health and progression toward malnutrition, cirrhosis, and liver cancer.
- Perform the appropriate diagnostic tests required to ensure early diagnosis of hepatocellular carcinoma.
- Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number.
- Review the current therapies for PBC and clinical approaches for PSC.
- Discover the pathway and barriers to liver disease elimination and the unique challenges of social populations.
- Learn about diagnostic tests for NASH that may soon be in daily use.
- Dine into the reasons Fatty Liver Disease and NASH are fast becoming a global health emergency.
- Utilize current clinical cases to improve diagnostic and treatment skills.
- Improve the health of patients infected with hepatitis virus, liver cancer and other progressive liver diseases.

REGISTRATION INFORMATION
Live weekend Early Registration Live weekend Regular Registration Including Mater.
Physicians, Clinical Pharmacists and Administrators $995 $975 $955 Nurse Practitioners and PA's $995 $975 $955 Medical Residents and Fellows $75 $85 $60


Cancellation Policy: Requests for cancellation must be submitted to cmepld@louisville.edu at least seven (7) days prior to the program date. Such requests will receive a full refund less a $20 processing fee.

WHO SHOULD ATTEND?
This program was developed for Gastroenterologists, Internists, Hepatologists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists.

PROGRAM HIGHLIGHTS
The seminar topics are presented in live presentations and supplemented by multi-media pre and post-course assignments. This allows us to make the most of our time together for group discussion, case analysis and patient management approaches.

- Viral Hepatitis
- The discovery of HCV and its natural history
- HCV Diagnosis and Treatment updates
- Epidemiology of Hepatitis B and the best Anti-viral therapies
- The growing incidence of Delta Hepatitis and its relationship to HBV
- Clinical cases to explore End-stage Liver Disease and Transplant options
- Why are Liver Cancer cases growing at alarming rates and What can be done?
- New and emerging therapies showing promise for the treatment of Hepatocellular Carcinoma
- Alcohol-associated liver disease
- Diagnosing and treating Hepatorenal Syndrome, Hepatic Encephalopathy, and Thrombocytopenia
- The explosion in Fatty Liver Disease and NASH and the unique challenges of special populations.
- Alcohol-associated liver disease
- Diagnosing and treating Hepatorenal Syndrome, Hepatic Encephalopathy, and Thrombocytopenia
- The explosion in Fatty Liver Disease and NASH and the unique challenges of special populations.
- Explore the factors that have led to reactivation of Hepatitis B and the diagnosis and treatment guidelines for Delta Hepatitis
- Formulate and implement strategies for preventing, diagnosing, treating, and/or referring patients with viral hepatitis
- Summarize the leading causes of the progression of chronic liver disease, hepatorenal syndrome, ascites, and hepatic encephalopathy.
- Discuss the current/emerging therapies for liver disease
- Explore the impact of alcohol on liver health and progression toward malnutrition, cirrhosis, and liver cancer.
- Perform the appropriate diagnostic tests required to ensure early diagnosis of hepatocellular carcinoma.
- Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number.
- Review the current therapies for PBC and clinical approaches for PSC.
- Discover the pathway and barriers to liver disease elimination and the unique challenges of social populations.
- Learn about diagnostic tests for NASH that may soon be in daily use.
- Dine into the reasons Fatty Liver Disease and NASH are fast becoming a global health emergency.
- Utilize current clinical cases to improve diagnostic and treatment skills.
- Improve the health of patients infected with hepatitis virus, liver cancer and other progressive liver diseases.

SPONSORS
The mission of the University of Louisville Continuing Medical Education & Professional Development program is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit http://louisville.edu/medicine/cme.